Uncategorized
Horizon Therapeutics plc Announces Teprotumumab Expanded Access Program
DUBLIN--(BUSINESS WIRE)--Horizon announces the availability of an expanded access program for its investigational medicine teprotumumab for active thyroid eye disease.